JP2005520779A5 - - Google Patents

Download PDF

Info

Publication number
JP2005520779A5
JP2005520779A5 JP2003511763A JP2003511763A JP2005520779A5 JP 2005520779 A5 JP2005520779 A5 JP 2005520779A5 JP 2003511763 A JP2003511763 A JP 2003511763A JP 2003511763 A JP2003511763 A JP 2003511763A JP 2005520779 A5 JP2005520779 A5 JP 2005520779A5
Authority
JP
Japan
Prior art keywords
clomiphene
pharmaceutically acceptable
trans
cis
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003511763A
Other languages
English (en)
Japanese (ja)
Other versions
JP4845165B2 (ja
JP2005520779A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/021524 external-priority patent/WO2003005954A2/en
Publication of JP2005520779A publication Critical patent/JP2005520779A/ja
Publication of JP2005520779A5 publication Critical patent/JP2005520779A5/ja
Application granted granted Critical
Publication of JP4845165B2 publication Critical patent/JP4845165B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003511763A 2001-07-09 2002-07-09 男性におけるテストステロン欠損の処置のための方法および物質 Expired - Fee Related JP4845165B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30431301P 2001-07-09 2001-07-09
US60/304,313 2001-07-09
PCT/US2002/021524 WO2003005954A2 (en) 2001-07-09 2002-07-09 Methods and materials for the treatment of testosterone deficiency in men

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009204154A Division JP2009280623A (ja) 2001-07-09 2009-09-03 男性におけるテストステロン欠損の処置のための方法および物質

Publications (3)

Publication Number Publication Date
JP2005520779A JP2005520779A (ja) 2005-07-14
JP2005520779A5 true JP2005520779A5 (cg-RX-API-DMAC10.html) 2006-01-05
JP4845165B2 JP4845165B2 (ja) 2011-12-28

Family

ID=23175972

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003511763A Expired - Fee Related JP4845165B2 (ja) 2001-07-09 2002-07-09 男性におけるテストステロン欠損の処置のための方法および物質
JP2009204154A Withdrawn JP2009280623A (ja) 2001-07-09 2009-09-03 男性におけるテストステロン欠損の処置のための方法および物質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009204154A Withdrawn JP2009280623A (ja) 2001-07-09 2009-09-03 男性におけるテストステロン欠損の処置のための方法および物質

Country Status (23)

Country Link
US (6) US7759360B2 (cg-RX-API-DMAC10.html)
EP (1) EP1411916B1 (cg-RX-API-DMAC10.html)
JP (2) JP4845165B2 (cg-RX-API-DMAC10.html)
KR (1) KR100851648B1 (cg-RX-API-DMAC10.html)
CN (2) CN1289075C (cg-RX-API-DMAC10.html)
AT (1) ATE406153T1 (cg-RX-API-DMAC10.html)
AU (1) AU2002318225B2 (cg-RX-API-DMAC10.html)
BR (1) BR0211067A (cg-RX-API-DMAC10.html)
CA (2) CA2777199A1 (cg-RX-API-DMAC10.html)
CL (1) CL2004000026A1 (cg-RX-API-DMAC10.html)
CO (1) CO5550428A2 (cg-RX-API-DMAC10.html)
CY (1) CY1108563T1 (cg-RX-API-DMAC10.html)
DE (1) DE60228583D1 (cg-RX-API-DMAC10.html)
DK (1) DK1411916T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP044937A (cg-RX-API-DMAC10.html)
ES (1) ES2312593T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA04000097A (cg-RX-API-DMAC10.html)
NZ (2) NZ530491A (cg-RX-API-DMAC10.html)
PL (1) PL211339B1 (cg-RX-API-DMAC10.html)
PT (1) PT1411916E (cg-RX-API-DMAC10.html)
RU (1) RU2297218C2 (cg-RX-API-DMAC10.html)
WO (1) WO2003005954A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200400142B (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1289075C (zh) 2001-07-09 2006-12-13 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物的用途
US7737185B2 (en) 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
EP1776098A1 (en) * 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
WO2006084153A2 (en) * 2005-02-04 2006-08-10 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
NZ560551A (en) * 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
US20080312239A1 (en) * 2007-06-13 2008-12-18 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
US20110118355A1 (en) * 2007-09-21 2011-05-19 Harry Fisch Treatment of migraine headaches using antiestrogens
US20090105348A1 (en) * 2007-10-18 2009-04-23 Harry Fisch Treatment of migraine headaches using antiestrogens
MX2010004195A (es) * 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.
US20090215738A1 (en) * 2008-02-26 2009-08-27 Michael Charles Scally Prevention and treatment of an increase in cardiovascular risk, adverse cardiovascular events, infertility, and adverse psychological effects after androgen or gnrh analogue intake
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
RU2474424C2 (ru) * 2010-09-24 2013-02-10 Государственное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
WO2013020215A1 (en) * 2011-08-09 2013-02-14 Adams Kenneth W Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
CA2872644A1 (en) 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins
SG10201704820SA (en) 2012-08-21 2017-07-28 Repros Therapeutics Inc Trans-clomiphene formulations and uses thereof
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
CN104994877A (zh) 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬
US9814687B2 (en) * 2014-08-20 2017-11-14 Professional Compounding Centers Of America Transdermal pharmaceutical compositions including C-SERMs for low testosterone levels in men
RU2586305C1 (ru) * 2015-02-02 2016-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения обструктивной азооспермии и криптозооспермии у пациентов с хроническим простатитом
CN108463453A (zh) 2016-04-22 2018-08-28 意大利合成制造有限公司 用于制备具有针状晶体习性的柠檬酸恩氯米芬的方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) * 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0206021B1 (de) 1985-06-08 1988-08-10 ASTA Pharma AG Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8926171D0 (en) 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
WO1995035093A1 (en) 1994-06-17 1995-12-28 University Of Nebraska Board Of Regents In situ gel-forming delivery vehicle for bio-affecting substances, and method of use
RU2089188C1 (ru) * 1994-07-13 1997-09-10 Владимир Александрович Божедомов Способ лечения мужского секреторного бесплодия
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
CA2228610C (en) * 1995-08-17 2008-06-03 Heidi Rolfes Controlled release products
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
ATE277739T1 (de) * 1996-10-28 2004-10-15 Gen Mills Inc Einbettung und einkapselung von teilchen zur kontrollierten abgabe
JP4496316B2 (ja) * 1997-04-03 2010-07-07 エーザイ インコーポレイテッド 生分解性テレフタレートポリエステル−ポリホスフェートポリマー、組成物、物品、並びにその製造及び使用方法
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
DE69935335T2 (de) * 1998-08-07 2007-11-22 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazole als modulatoren des östrogenrezeptors
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP5184727B2 (ja) * 1999-06-11 2013-04-17 ワトソン ファーマシューティカルズ， インコーポレイテッド 女性への非経口アンドロゲンステロイドの投与
CA2321321A1 (en) * 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
US20020004065A1 (en) * 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
WO2001091744A1 (en) 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
ATE278421T1 (de) 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002213198A1 (en) 2000-10-11 2002-04-22 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
US6743448B2 (en) * 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
CN1289075C (zh) 2001-07-09 2006-12-13 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物的用途
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
EP1429779A2 (en) 2001-09-21 2004-06-23 Merck & Co., Inc. Androstanes as androgen receptor modulators
US6600110B1 (en) * 2001-10-01 2003-07-29 Gram Precision Portable digital readout scale
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) * 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
JP4312522B2 (ja) 2003-06-30 2009-08-12 株式会社リコー 現像剤補給方法、現像剤補給装置、及び、画像形成装置
EP1776098A1 (en) 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
WO2006084153A2 (en) 2005-02-04 2006-08-10 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
EP1853298A2 (en) 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
NZ560551A (en) 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
US20080306035A1 (en) 2005-08-05 2008-12-11 Repros Therapeutics Inc. Methods and Compositions for Treating Female Infertility Using Clomiphene
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
MX2010004195A (es) 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.
US20100111901A1 (en) 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TWI458478B (zh) 2008-11-07 2014-11-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
WO2013020215A1 (en) 2011-08-09 2013-02-14 Adams Kenneth W Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males

Similar Documents

Publication Publication Date Title
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
WO2009040045A3 (en) Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
NZ610715A (en) Antiviral compounds and methods
WO2009046865A3 (en) Cholecystokinin-33 alone or in combination with trap-14 as therapeutic agent
WO2009046834A3 (en) Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections
CA2453337A1 (en) Methods and materials for the treatment of testosterone deficiency in men
WO2013016697A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
NO20032510D0 (no) Organiske forbindelser
WO2009033784A3 (en) Use of apelin-13 (qrprlshkgpmpf) and optionally aplha-casein (90-96) as a therapeutic agents in eg the treatment of hiv infection
WO2009040049A3 (en) Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents
CA2476201A1 (en) Modified release formulations of at least one form of tramadol
JP2002519434A5 (cg-RX-API-DMAC10.html)
JP2004516314A5 (cg-RX-API-DMAC10.html)
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
JP2003531118A5 (cg-RX-API-DMAC10.html)
WO2006069155A3 (en) Inhibitors of protein arginine methyl transferases
WO2009043454A3 (en) Use of pacap-27 as a therapeutic agent
WO2009046867A3 (en) Caerulein alone or in combination with acth (3-24 ) as therapeutic agent
CO5280073A1 (es) Composiciones
WO2009040005A3 (en) Use of the peptide rfmwmr as a therapeutic agent
WO2009033791A3 (en) Use of a peptide as a therapeutic agent
WO2009046858A3 (en) Therapeutic uses of kisspeptin 13 and compositions thereof
JP2003503449A5 (cg-RX-API-DMAC10.html)
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
SE0102440D0 (sv) New compound